[
  {
    "date": "2022-12-30",
    "symbol": "OCX",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2022,
    "currentfiscalyearenddate": "December 31",
    "entityfilenumber": "1-37648",
    "entityregistrantname": "OncocyteCorporation",
    "entitycentralindexkey": 1642380,
    "entitytaxidentificationnumber": "27-1041563",
    "entityincorporationstatecountrycode": "California",
    "entityaddressaddressline1": "15Cushing",
    "entityaddresscityortown": "Irvine",
    "entityaddressstateorprovince": "California",
    "entityaddresspostalzipcode": 92618,
    "cityareacode": "(949)",
    "localphonenumber": "409-7600",
    "security12btitle": "Common    Stock, no par value",
    "tradingsymbol": "OCX",
    "securityexchangename": "Nasdaq",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated    filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "No",
    "icfrauditorattestationflag": "false",
    "auditorname": "WithumSmith+Brown, PC",
    "auditorlocation": "East Brunswick, New Jersey",
    "auditorfirmid": 100,
    "cashandcashequivalentsatcarryingvalue": 19993000,
    "accountsreceivablenetcurrent": 2012000,
    "equitysecuritiesfvni": 19000,
    "prepaidexpenseandotherassetscurrent": 977000,
    "assetsofdisposalgroupincludingdiscontinuedoperationcurrent": 2121000,
    "assetscurrent": 25536000,
    "financeleaserightofuseasset": 91000,
    "machineryandequipmentnetandconstructioninprogress": 8763000,
    "intangibleassetsnetexcludinggoodwill": 61633000,
    "restrictedcashnoncurrent": 1700000,
    "otherassetsnoncurrent": 371000,
    "disposalgroupincludingdiscontinuedoperationassetsnoncurrent": 2121000,
    "assets": 100091000,
    "accountspayablecurrent": 1253000,
    "accruedliabilitiescurrent": 1771000,
    "accountspayableandotheraccruedliabilitiescurrent": 3839000,
    "accruedseverancefromacquisitioncurrent": 2314000,
    "businesscombinationcontingentconsiderationliabilitycurrent": 109000,
    "operatingleaseandfinancingleaseliabilitiescurrent": 815000,
    "liabilitiesofdisposalgroupincludingdiscontinuedoperationcurrent": 2005000,
    "liabilitiescurrent": 12106000,
    "operatingleaseliabilitiesandfinancingleaseliabilitiesnoncurrent": 2729000,
    "businesscombinationcontingentconsiderationliabilitynoncurrent": 45662000,
    "liabilities": 60497000,
    "temporaryequitycarryingamountattributabletoparent": 5302000,
    "commonstockvalue": 5000000,
    "accumulatedothercomprehensiveincomelossnetoftax": 39000,
    "retainedearningsaccumulateddeficit": -260676000,
    "stockholdersequity": -260676000,
    "liabilitiesandstockholdersequity": 100091000,
    "allowancefordoubtfulaccountsreceivable": 154000,
    "temporaryequityparorstatedvaluepershare": 1000000,
    "temporaryequitysharesissued": 5882.4,
    "temporaryequitysharesoutstanding": 6000,
    "temporaryequityliquidationpreference": 6091000,
    "preferredstocksharesauthorized": 5000000,
    "commonstocksharesauthorized": "null",
    "commonstocksharesissued": 118644000,
    "commonstocksharesoutstanding": 118644000,
    "revenuefromcontractwithcustomerexcludingassessedtax": 958000,
    "costofrevenue": 880000,
    "costofrevenuesamortizationofacquiredintangibles": 96000,
    "grossprofit": -18000,
    "researchanddevelopmentexpense": 7301000,
    "sellingandmarketingexpense": 1132000,
    "generalandadministrativeexpense": 21881000,
    "businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsiderationliability1": -31019000,
    "goodwillimpairmentloss": 18684000,
    "operatingexpenses": 17979000,
    "operatingincomeloss": 10000,
    "interestincomeexpensenet": -77000,
    "marketablesecuritiesunrealizedgainloss": -471000,
    "othernonoperatingincomeexpense": -67000,
    "nonoperatingincomeexpense": -615000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -18612000,
    "incometaxexpensebenefit": -1200000,
    "incomelossfromcontinuingoperationsincludingportionattributabletononcontrollinginterest": -18612000,
    "incomelossfromdiscontinuedoperationsnetoftax": -54290000,
    "netincomeloss": -72902000,
    "accretionofseriesredeemableconvertiblepreferredstock": 520000,
    "netincomelossavailabletocommonstockholdersbasic": -73422000,
    "incomelossfromcontinuingoperationsperbasicshare": -0.17,
    "incomelossfromdiscontinuedoperationsnetoftaxperbasicshare": -0.49,
    "earningspersharebasic": -0.66,
    "weightedaveragenumberofsharesoutstandingbasic": 110800,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 2000,
    "comprehensiveincomenetoftax": -72900000,
    "sharesoutstanding": 118644000,
    "stockissuedduringperiodvaluesharebasedcompensationgross": 10042000,
    "stockissuedduringperiodsharesrestrictedstockawardnetofforfeitures": 131000,
    "stockissuedduringperiodvalueissuanceofcommonsharesincludingatthemarkettransactionsnetoffinancingcostsandunderwritingdiscounts": 32453000,
    "stockissuedduringperiodsharesissuanceofcommonsharesincludingatthemarkettransactionsnetoffinancingcostsandunderwritingdiscounts": 26281000,
    "stockissuedduringperiodvalueconversionofunits": 4782000,
    "stockissuedduringperiodsharesconversionofunits": 5882000,
    "stockissuedduringperiodvalueaccretionofseriesconvertiblepreferredstocktoredemptionvalue": -520000,
    "depreciation": 1528000,
    "amortizationofintangibleassets": 3692000,
    "sharebasedcompensation": 10042000,
    "amortizationoffinancingcosts": 12000,
    "gainlossonsaleofleasedassetsnetoperatingleases": -25866000,
    "increasedecreaseinaccountsreceivable": 575000,
    "increasedecreaseinoperatingleaseliability": -116000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 231000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 297000,
    "accruedseveranceandliabilitiesfromchronixbiomedicalacquisition": 1317000,
    "netcashprovidedbyusedinoperatingactivities": -45568000,
    "paymentstoacquirepropertyplantandequipment": 4340000,
    "netcashprovidedbyusedininvestingactivities": -4340000,
    "proceedsfromissuanceofcommonstock": 32812000,
    "paymentsofstockissuancecosts": 389000,
    "proceedsfromsaleofredeemableconvertibleseriespreferredshares": 4875000,
    "financingcoststoissueredeemableconvertibleseriespreferredshares": 93000,
    "proceedsfromsaleofcommonsharesunderatthemarkettransactions": 31000,
    "paymentforfinancingcostsforatthemarketsales": 1000,
    "repaymentsofdebt": 1325000,
    "repaymentoffinancingleaseobligations": 104000,
    "netcashprovidedbyusedinfinancingactivities": 35806000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -14102000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 23203000,
    "interestpaidnet": 24000,
    "constructioninprogressmachineryandequipmentpurchasesincludedinaccountspayableaccruedliabilitiesandlandlordliability": 323000,
    "stockissuedduringperiodvaluenewissues": 3000000,
    "saleofstockpricepershare": 5.58,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 5.46,
    "assetsfairvaluedisclosure": 433000,
    "liabilitiesfairvaluedisclosure": 45662000,
    "restrictedcash": 1700000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsdisposalgroupincludingdiscontinuedoperations": 1510000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 23203000,
    "redeemablepreferredstockdividends": 520000,
    "dilutivesecurities": 33941000,
    "commonstocksharesheldasavailableforsalesecurities": 35326,
    "propertyplantandequipmentusefullife": 10,
    "lesseeoperatingleasetermofcontract": 5,
    "finitelivedintangibleassetusefullife": 5,
    "accountsreceivablesale": 300000,
    "provisionfordoubtfulaccounts": 200000,
    "cashfdicinsuredamount": 250000,
    "contingentconsiderationliabilitycontractualvalue": 6000000,
    "businesscombinationcontingentconsiderationliability": 40292000,
    "businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsiderationliabilityasset": -29329000,
    "financeleaseweightedaveragediscountratepercent": 0.1155,
    "fairvalueofcontingentconsideration": 29300000,
    "clinicaltrialexpensereserveamount": 4000000,
    "estimatedclinicaltrialexpense": 16000000,
    "researchanddevelopmentarrangementcontracttoperformforotherscostsincurredgross": 3000000,
    "paymentobligationamount": 124000,
    "leaseexpirationdate1": "September29, 2021",
    "indefinitelivedintangibleassetsacquired": 46800000,
    "acquiredfinitelivedintangibleassetresidualvalue": 440000,
    "intangibleassetsgrossexcludinggoodwill": 61890000,
    "finitelivedintangibleassetsaccumulatedamortization": -257000,
    "finitelivedintangibleassetsamortizationexpensenexttwelvemonths": 88000,
    "finitelivedintangibleassetsamortizationexpenseyeartwo": 88000,
    "finitelivedintangibleassetsamortizationexpenseyearthree": 7000,
    "finitelivedintangibleassetsnet": 183000,
    "temporaryequitysharesauthorized": 11765,
    "equityfairvaluedisclosure": 400000,
    "classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.024300000000000002,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 6.01,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.0674,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaveragegrantdatefairvalue": 1.13,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 10805000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 8560000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 2.96,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 6484000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 2.8,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 5256000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageexerciseprice1": 4.76,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 441000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablerestrictedstockoptionsvestedinperiod": 341000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodrsus": -341000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablerestrictedstockoptionsgrantsinperiodgross": -511000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodrsus": 511000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailableperformancerestrictedstockoptionsgrantsinperiodgross": -1150000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodperformancersus": 1150000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailableperformancerestrictedstockoptionsvestedinperiodgross": 425000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodperformancersus": -425000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablegrantsinperiodgross": -4365000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 4365000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 1.1,
    "stockissuedduringperiodsharesstockoptionsnonvestedoptionsforfeited": 6484000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedrestrictedstockoptionsforfeitednumberofshares": 575000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsrestrictedstockoptionsforfeited": 575000,
    "allocatedsharebasedcompensationexpense": 10042000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": "null",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgrantdatefairvalue": 117625,
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "50% of the performance-based were forfeited since the Company did not achieve LCD reimbursement for VitaGraft.",
    "increasedecreaseinfairvalueadjustmentsonassetsandliabilitiescarriedatfairvalueunderfairvalueoption": 58500,
    "concentrationriskpercentage1": 0.65,
    "deferredtaxassetsoperatinglosscarryforwards": 103800000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 2400000,
    "deferredtaxassetsequitymethodinvestments": 364000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 5067000,
    "deferredtaxrightofuseliability": 952000,
    "deferredtaxinvestment": 5373000,
    "deferredtaxassetscapitalizedresearchanddevelopment": 4011000,
    "deferredtaxassetsothertaxcarryforwards": 49000,
    "deferredtaxassetsgross": 71798000,
    "deferredtaxassetsvaluationallowance": 54408000,
    "deferredtaxassetsnet": 17390000,
    "deferredtaxrightofuseasset": -580000,
    "deferredtaxassetsintangiblesandfixedassets": -16810000,
    "deferredincometaxliabilities": 17390000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": -0.14,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.01,
    "effectiveincometaxratereconciliationtaxcreditsresearch": -0.03,
    "effectiveincometaxratereconciliationchangeinfairvalueconsideration": 0.35000000000000003,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.19,
    "effectiveincometaxrategoodwillimpairment": -0.21,
    "unrecognizedtaxbenefits": 1900000,
    "unrecognizedtaxbenefitsincreasesresultingfromcurrentperiodtaxpositions": 531000,
    "operatinglosscarryforwards": 72900000,
    "netoperatinglossexpirationperioddescription": "between2023 and 2042",
    "creditcarryforwardexpirationterm": "between 2030 and 2042",
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 17200000,
    "otherinformationpertainingtoincometaxes": "InternalRevenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offsetby NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a losscorporation.",
    "operatingleaserightofuseasset": 2088000,
    "operatingleaserightofuseassetstatementoffinancialpositionextensiblelist": "http://oncocyte.com/20221231#MachineryAndEquipmentNetAndConstructionInProgress",
    "machineryandequipmentgross": 9408000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 4196000,
    "propertyplantandequipmentnet": 8711000,
    "constructioninprogressgross": 2140000,
    "rightofuseassetsmachineryandequipmentcontinuingoperations": 10851000,
    "rightofuseassetsmachineryandequipmentdiscontinuingoperations": 211000,
    "rightofuseassetsmachineryandequipmentnet": 11062000,
    "depreciationandamortization": 1500000,
    "operatingleasepayments": 1143000,
    "financeleaseinterestpaymentonliability": 20000,
    "financeleaseprincipalpayments": 104000,
    "operatingleaseliabilitycurrent": 698000,
    "operatingleaseliabilitycurrentstatementoffinancialpositionextensiblelist": "http://oncocyte.com/20221231#OperatingLeaseAndFinancingLeaseLiabilitiesCurrent",
    "operatingleaseliabilitynoncurrent": 2730000,
    "operatingleaseliabilitynoncurrentstatementoffinancialpositionextensiblelist": "http://oncocyte.com/20221231#OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent",
    "operatingleaseliability": 3428000,
    "financeleaserightofuseassetbeforeaccumulatedamortization": 537000,
    "financeleaserightofuseassetaccumulatedamortization": 446000,
    "financeleaserightofuseassetstatementoffinancialpositionextensiblelist": "http://oncocyte.com/20221231#MachineryAndEquipmentNetAndConstructionInProgress",
    "financeleaseliabilitycurrent": 117000,
    "financeleaseliabilitycurrentstatementoffinancialpositionextensiblelist": "http://oncocyte.com/20221231#OperatingLeaseAndFinancingLeaseLiabilitiesCurrent",
    "financeleaseliabilitynoncurrentstatementoffinancialpositionextensiblelist": "http://oncocyte.com/20221231#OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent",
    "financeleaseliability": 117000,
    "operatingleaseweightedaverageremainingleaseterm1": 4.5,
    "financeleaseweightedaverageremainingleaseterm1": 1,
    "operatingleaseweightedaveragediscountratepercent": 0.1124,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 1048000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 903000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 869000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 899000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 694000,
    "lesseeoperatingleaseliabilitypaymentsdue": 4413000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 985000,
    "presentvalueofnetminimumleasepayments": 3428000,
    "financeleaseliabilitypaymentsduenexttwelvemonths": 124000,
    "financeleaseliabilitypaymentsdue": 124000,
    "financeleaseliabilityundiscountedexcessamount": 7000,
    "paymentsduetothelandlordforearlycancellation": 39000,
    "severancecosts1": 1900000,
    "lineofcreditfacilityinterestrateatperiodend": 0.055,
    "paymentstoacquireproductiveassets": 1900000,
    "developmentcosts": 749000,
    "productdevelopmentbudget": 5000000,
    "preferredstockdividendratepercentage": 0.06,
    "dividendspreferredstock": 209000,
    "disposalgroupincludingdiscontinuedoperationrevenue": 4673000,
    "disposalgroupincludingdiscontinuedoperationcostsofgoodssold": 7930000,
    "disposalgroupincludingdiscontinuedoperationresearchanddevelopment": 12136000,
    "disposalgroupincludingdiscontinuedoperationsalesandmarketing": 12462000,
    "disposalgroupincludingdiscontinuedoperationgeneralandadministrativeexpense": 569000,
    "incomelossfromindividuallysignificantcomponentdisposedoforheldforsaleexcludingdiscontinuedoperationsattributabletononcontrollinginterestbeforeincometax": 25866000,
    "disposalgroupincludingdiscontinuedoperationcashandcashequivalents": 1510000,
    "disposalgroupincludingdiscontinuedoperationprepaidandotherassetscurrent": 346000,
    "disposalgroupincludingdiscontinuedoperationmachineryandequipment": 211000,
    "disposalgroupincludingdiscontinuedoperationintangibleassetscurrent": 25920000,
    "disposalgroupincludingdiscontinuedoperationimpairmentofheldforsales": -25866000,
    "assetsofdisposalgroupincludingandimpairmentofsalediscontinuedoperationcurrent": -2121000,
    "disposalgroupincludingdiscontinuedoperationaccountspayablecurrent": 492000,
    "disposalgroupincludingdiscontinuedoperationaccruedcompensation": 248000,
    "disposalgroupincludingdiscontinuedoperationaccruedexpensesothercurrentliabilities": 1265000,
    "cashprovidedbyusedinoperatingactivitiesdiscontinuedoperations": -20790000,
    "cashprovidedbyusedininvestingactivitiesdiscontinuedoperations": -91000
  },
  {
    "date": "2021-12-30",
    "symbol": "OCX",
    "period": "FY",
    "documenttype": "10-K",
    "amendmentflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentperiodenddate": "2021-12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2021,
    "currentfiscalyearenddate": "--12-31",
    "entityfilenumber": "1-37648",
    "entityregistrantname": "Oncocyte Corporation",
    "entitycentralindexkey": 1642380,
    "entitytaxidentificationnumber": "27-1041563",
    "entityincorporationstatecountrycode": "CA",
    "entityaddressaddressline1": "15 Cushing",
    "entityaddresscityortown": "Irvine",
    "entityaddressstateorprovince": "CA",
    "entityaddresspostalzipcode": 92618,
    "cityareacode": "(949)",
    "localphonenumber": "409-7600",
    "security12btitle": "Common     Stock, no par value",
    "tradingsymbol": "OCX",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "icfrauditorattestationflag": "false",
    "auditorfirmid": 100,
    "auditorname": "Withum Smith+Brown, PC",
    "auditorlocation": "San Francisco, California",
    "cashandcashequivalentsatcarryingvalue": 35605000,
    "accountsreceivablenetcurrent": 1437000,
    "equitysecuritiesfvni": 904000,
    "prepaidexpenseandotherassetscurrent": 1197000,
    "assetscurrent": 39143000,
    "financeleaserightofuseasset": 2779000,
    "machineryandequipmentnetandconstructioninprogress": 5748000,
    "goodwill": 18684000,
    "intangibleassetsnetexcludinggoodwill": 91245000,
    "restrictedcashnoncurrent": 1700000,
    "otherassetsnoncurrent": 264000,
    "assets": 159563000,
    "accountspayablecurrent": 2447000,
    "accruedliabilitiescurrent": 3376000,
    "accountspayableandotheraccruedliabilitiescurrent": 2425000,
    "accruedseverancefromacquisitioncurrent": 2352000,
    "businesscombinationcontingentconsiderationliabilitycurrent": 1388000,
    "loanspayablecurrent": 1313000,
    "operatingleaseandfinancingleaseliabilitiescurrent": 819000,
    "liabilitiescurrent": 14120000,
    "operatingleaseliabilitiesandfinancingleaseliabilitiesnoncurrent": 3545000,
    "businesscombinationcontingentconsiderationliabilitynoncurrent": 76681000,
    "liabilities": 94346000,
    "commonstockvalue": 252954000,
    "accumulatedothercomprehensiveincomelossnetoftax": 37000,
    "retainedearningsaccumulateddeficit": -187774000,
    "stockholdersequity": 65217000,
    "liabilitiesandstockholdersequity": 159563000,
    "preferredstocksharesauthorized": 5000000,
    "commonstocksharesauthorized": 230000000,
    "commonstocksharesissued": 92232000,
    "commonstocksharesoutstanding": 92232000,
    "revenuefromcontractwithcustomerexcludingassessedtax": 7727000,
    "costofrevenue": 4185000,
    "costofrevenuesamortizationofacquiredintangibles": 3354000,
    "grossprofit": 188000,
    "researchanddevelopmentexpense": 13631000,
    "sellingandmarketingexpense": 11167000,
    "generalandadministrativeexpense": 22336000,
    "businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsiderationliability1": 27266000,
    "operatingexpenses": 74400000,
    "operatingincomeloss": -74212000,
    "interestincomeexpensenet": -209000,
    "marketablesecuritiesunrealizedgainloss": 229000,
    "incomelossfromequitymethodinvestments": -270000,
    "gainslossesonextinguishmentofdebt": 1141000,
    "othernonoperatingincomeexpense": -37000,
    "nonoperatingincomeexpense": 854000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -73358000,
    "incometaxexpensebenefit": -9261000,
    "netincomeloss": -64097000,
    "earningspersharebasicanddiluted": -0.72,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 88920,
    "othercomprehensiveincomelossforeigncurrencytransactionandtranslationadjustmentnetoftax": 37000,
    "comprehensiveincomenetoftax": -64060000,
    "sharesoutstanding": 92232000,
    "stockissuedduringperiodvaluesharebasedcompensationgross": 6841000,
    "stockissuedduringperiodvaluenewissues": 3000000,
    "stockissuedduringperiodvalueother": -3065000,
    "stockissuedduringperiodvalueofsaleofcommonsharesunderatthemarkettransactions": 77987000,
    "stockissuedduringperiodsharessaleofcommonsharesunderatthemarkettransactionsshares": 19536000,
    "stockissuedduringperiodvaluestockoptionsexercised": 2584000,
    "stockissuedduringperiodsharesstockoptionsexercised": 924000,
    "stockissuedduringperiodvaluewarrantsexercised": 2631000,
    "stockissuedduringperiodshareswarrantsexercised": 872000,
    "sharesissueduponvestingofrsunetofsharesretiredtopayemployeestaxes": -239000,
    "sharesissueduponvestingofrsunetofsharesretiredtopayemployeestaxesshares": 153000,
    "stockissuedduringperiodvalueacquisitionsone": 5756000,
    "stockissuedduringperiodsharesacquisitionsone": 982000,
    "stockissuedduringperiodvalueacquisitionstwo": 3299000,
    "stockissuedduringperiodsharesacquisitionstwo": 648000,
    "adjustmentstoforeigncurrencytranslation": 37000,
    "depreciation": 844000,
    "amortizationofintangibleassets": 3361000,
    "sharebasedcompensation": 6841000,
    "amortizationoffinancingcosts": 56000,
    "deferredincometaxexpensebenefit": -9261000,
    "increasedecreaseinaccountsreceivable": 1229000,
    "increasedecreaseinoperatingleaseliability": 147000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -227000,
    "increasedecreaseinaccountspayableandaccruedliabilities": -1348000,
    "accruedseverancefromchronixbiomedicalacquisition": 2352000,
    "netcashprovidedbyusedinoperatingactivities": -35941000,
    "paymentstoacquirebusinessesnetofcashacquired": 607000,
    "acquisitionofrazorgenomicsassetnetofcashacquired": 6648000,
    "acquisitionofchronixbiomedicalnetofcashacquired": 4459000,
    "paymentstoacquirepropertyplantandequipment": 2247000,
    "netcashprovidedbyusedininvestingactivities": -13961000,
    "proceedsfromstockoptionsexercised": 2584000,
    "proceedsfromissuanceofcommonstock": 65263000,
    "paymentsofstockissuancecosts": 2675000,
    "proceedsfromissuanceofprivateplacement": 12724000,
    "paymentforfinancingcostsforatthemarketsales": 390000,
    "proceedsfromwarrantexercises": 2631000,
    "commonsharesreceivedandretiredforemployeetaxespaid": 239000,
    "repaymentsofdebt": 1500000,
    "repaymentoffinancingleaseobligations": 34000,
    "netcashprovidedbyusedinfinancingactivities": 78364000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 28462000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 37305000,
    "interestpaidnet": 114000,
    "commonstockissuedforacquisition": 5756000,
    "deferredtaxliabilitygeneratedfromacquisitionofrazorgenomicsasset": 7077000,
    "commonstockissuedforacquisitionofchronixbiomedical": 3299000,
    "deferredtaxliabilitygeneratedfromacquisitionofchronix": 2183000,
    "initialfairvalueofcontingentconsiderationatacquisitiondate": 42295000,
    "assumedliabilityfromchronixacquisition": 3352000,
    "constructioninprogressmachineryandequipmentpurchasesincludedinaccountspayableaccruedliabilitiesandlandlordliability": 1083000,
    "saleofstockpricepershare": 5.63,
    "prepaidvendorsdepositsandserviceagreements": 365000,
    "suppliesinventory": 304000,
    "prepaidinsurance": 243000,
    "notereceivable": 200000,
    "otherassetscurrent": 85000,
    "restrictedcashincludedindepositsandothernoncurrentassets": 1700000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 4579000,
    "commonstocksharesheldasavailableforsalesecurities": 353264000,
    "propertyplantandequipmentusefullife": "P3Y",
    "lesseeoperatingleasetermofcontract": "P3Y",
    "finitelivedintangibleassetusefullife": "P5Y",
    "accountsreceivablesale": 1100000,
    "finitelivedintangibleassetestimatedfairvalue": 14650000,
    "contingentconsiderationliabilitycontractualvalue": 1500000,
    "businesscombinationcontingentconsiderationliability": 1340000,
    "financeleaseweightedaveragediscountratepercent": 0.1155,
    "fairvalueofcontingentconsideration": 60000000000,
    "clinicaltrialexpensereserveamount": 4000000,
    "estimatedclinicaltrialexpense": 16000000,
    "researchanddevelopmentarrangementcontracttoperformforotherscostsincurredgross": 3000000,
    "paymentobligationamount": 450000000,
    "leaseexpirationdate1": "2021-09-29",
    "businessacquisitioncostofacquiredentitytransactioncosts": 700000,
    "indefinitelivedintangibleassetsacquired": 14650000,
    "acquiredfinitelivedintangibleassetresidualvalue": 440000,
    "intangibleassetsgrossexcludinggoodwill": 94687000,
    "finitelivedintangibleassetsaccumulatedamortization": -169000,
    "finitelivedintangibleassetsamortizationexpensenexttwelvemonths": 3856000,
    "finitelivedintangibleassetsamortizationexpenseyeartwo": 3904000,
    "finitelivedintangibleassetsamortizationexpenseyearthree": 3904000,
    "finitelivedintangibleassetsamortizationexpenseyearfour": 3823000,
    "finitelivedintangibleassetsamortizationexpenseyearfive": 3816000,
    "finitelivedintangibleassetsamortizationexpenseafteryearfive": 10493000,
    "finitelivedintangibleassetsnet": 29796000,
    "classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": 2251576,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 1.69,
    "warrantsandrightsoutstandingmaturitydate": "2029-10-17",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 9006000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 923000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 3.65,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestednumberofshares": 47500,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 2.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsforfeitednumberofshares": 1396000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 131000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 4.11,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 923000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageexerciseprice1": 3.65,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 121000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodrsus": -201000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablerestrictedstockoptionsgrantsinperiodgross": -121000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodrsus": 121000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsincreasenumberofshares": 10000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablegrantsinperiodgross": -5615000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 1000000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 4.72,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangelowerrangelimit": 2.12,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 3.8,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y11M23D",
    "allocatedsharebasedcompensationexpense": 101000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0102,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.9888,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 21000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "under the 2018 Incentive Plan must be equal to the fair market of Oncocyte common stock on the date theoption is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classesof Oncocyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stockon the grant date, and the term of the option may be no longer than five years.",
    "stockoptionexercisable": 100000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 19100000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P2Y8M12D",
    "concentrationriskpercentage1": 0.32,
    "deferredtaxassetsoperatinglosscarryforwards": 204800000,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 2400000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "effectiveincometaxratereconciliationforeignincometaxratedifferential": -0.01,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.02,
    "effectiveincometaxratereconciliationchangeinfairvalueconsideration": -0.08,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.01,
    "effectiveincometaxratecontinuingoperations": 0.13,
    "unrecognizedtaxbenefits": 1400000,
    "unrecognizedtaxbenefitsincreasesresultingfromcurrentperiodtaxpositions": 511000,
    "unrecognizedtaxbenefitsdecreasesresultingfromsettlementswithtaxingauthorities": 2173000,
    "netoperatinglossexpirationperioddescription": "between2022 and 2037",
    "creditcarryforwardexpirationterm": "between2030 and 2041",
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 5400000,
    "derecognizeduncertaintaxposition": 2200000,
    "otherinformationpertainingtoincometaxes": "InternalRevenue Code Section 382 places a limitation (“Section 382 Limitation”) on the amount of taxable income that can be offsetby NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a losscorporation.",
    "operatingleaserightofuseassets": 2579000,
    "propertyplantandequipmentgross": 6501000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 2715000,
    "propertyplantandequipmentnet": 7285000,
    "constructioninprogressgross": 1242000,
    "rightofuseassetsmachineryandequipmentnet": 8527000,
    "depreciationandamortization": 844000,
    "operatingleasepayments": 1042000,
    "financeleaseinterestpaymentonliability": 147000,
    "financeleaseprincipalpayments": 34000,
    "operatingleaseliabilitycurrent": 715000,
    "operatingleaseliabilitynoncurrent": 3428000,
    "operatingleaseliability": 4143000,
    "financeleaserightofuseassetbeforeaccumulatedamortization": 537000,
    "financeleaserightofuseassetaccumulatedamortization": 337000,
    "financeleaseliabilitycurrent": 104000,
    "financeleaseliabilitynoncurrent": 117000,
    "financeleaseliability": 221000,
    "operatingleaseweightedaverageremainingleaseterm1": "P5Y3M18D",
    "financeleaseweightedaverageremainingleaseterm1": "P2Y",
    "operatingleaseweightedaveragediscountratepercent": 0.1117,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 1143000,
    "financeleaseliabilitypaymentsduenexttwelvemonths": 124000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 1048000,
    "financeleaseliabilitypaymentsdueyeartwo": 124000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 903000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 869000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 899000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 695000,
    "lesseeoperatingleaseliabilitypaymentsdue": 5557000,
    "financeleaseliabilitypaymentsdue": 248000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 1413000,
    "financeleaseliabilityundiscountedexcessamount": 28000,
    "presentvalueofnetminimumleasepayments": 4144000,
    "paymentsforproceedsfromtenantallowance": 1300000,
    "paymentsduetothelandlordforearlycancellation": 192000,
    "severancecosts1": 2400000,
    "lineofcreditfacilityinterestrateatperiodend": 0.0325,
    "financingreceivableunamortizedloanfeecost": 12000
  },
  {
    "date": "2020-12-30",
    "symbol": "OCX",
    "period": "FY",
    "entityregistrantname": "OncoCyte Corp",
    "entitycentralindexkey": 1642380,
    "documenttype": "10-K",
    "documentperiodenddate": "2020-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "true",
    "entityshellcompany": "false",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2020,
    "cashandcashequivalentsatcarryingvalue": 7143000,
    "accountsreceivablenetcurrent": 203000,
    "equitysecuritiesfvni": 675000,
    "prepaidexpenseandotherassetscurrent": 1205000,
    "assetscurrent": 9226000,
    "rightofuseassetsmachineryandequipmentnet": 6524000,
    "equitymethodinvestments": 13417000,
    "goodwill": 9187000,
    "intangibleassetsnetexcludinggoodwill": 15009000,
    "depositsandothernoncurrentassets": 2056000,
    "assets": 55419000,
    "accountspayablecurrent": 432000,
    "accountspayableandotheraccruedliabilitiescurrent": 5752000,
    "loanspayablecurrent": 2390000,
    "operatingleaseandfinancingleaseliabilitiescurrent": 422000,
    "liabilitiescurrent": 8996000,
    "longtermloanspayable": 1508000,
    "operatingleaseliabilitiesandfinancingleaseliabilitiesnoncurrent": 4312000,
    "businesscombinationcontingentconsiderationliabilitynoncurrent": 7120000,
    "liabilities": 21936000,
    "commonstockvalue": 157160000,
    "retainedearningsaccumulateddeficit": -123677000,
    "stockholdersequity": -123677000,
    "liabilitiesandstockholdersequity": 55419000,
    "preferredstocksharesauthorized": 5000000,
    "commonstocksharesauthorized": 150000000,
    "commonstocksharesissued": 69117000,
    "commonstocksharesoutstanding": 69117000,
    "revenuefromcontractwithcustomerexcludingassessedtax": 1216000,
    "costofrevenue": 1855000,
    "researchanddevelopmentexpense": 691000,
    "generalandadministrativeexpense": 16788000,
    "sellingandmarketingexpense": 6494000,
    "businesscombinationcontingentconsiderationarrangementschangeinamountofcontingentconsiderationliability1": -4010000,
    "costsandoperatingexpenses": 30927000,
    "operatingincomeloss": -691000,
    "interestincomeexpensenet": -252000,
    "marketablesecuritiesunrealizedgainloss": 297000,
    "incomelossfromequitymethodinvestments": -1547000,
    "othernonoperatingincomeexpense": 27000,
    "nonoperatingincomeexpense": -1475000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -31186000,
    "incometaxexpensebenefit": -1254000,
    "netincomeloss": -691000,
    "earningspersharebasicanddiluted": -0.46,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 65478000,
    "comprehensiveincomenetoftax": -29932000,
    "sharesoutstanding": 69117000,
    "stockissuedduringperiodvaluesharebasedcompensationgross": 5066000,
    "stockissuedduringperiodvaluenewissues": 18343000,
    "stockissuedduringperiodsharesnewissues": 1136673,
    "stockissuedduringperiodvalueother": -58000,
    "stockissuedduringperiodvaluestockoptionsexercised": 1422000,
    "stockissuedduringperiodsharesstockoptionsexercised": 680000,
    "stockissuedduringperiodvalueofsaleofcommonsharesunderatthemarkettransactions": 2732000,
    "stockissuedduringperiodsharessaleofcommonsharesunderatthemarkettransactionsshares": 1137000,
    "stockissuedduringperiodvaluefinancingcostsforatthemarketsales": -82000,
    "sharesissueduponvestingofrsunetofsharesretiredtopayemployeestaxes": -15000,
    "sharesissueduponvestingofrsunetofsharesretiredtopayemployeestaxesshares": 13000,
    "stockissuedduringperiodvalueissuedforservices": 169000,
    "stockissuedduringperiodsharesissuedforservices": 82000,
    "stockissuedduringperiodvalueacquisitions": 5000000,
    "stockissuedduringperiodsharesacquisitions": 1916000,
    "depreciation": 313000,
    "amortizationofintangibleassets": 81000,
    "amortizationofrightofuseassetsandliabilities": 1504000,
    "impairmentoflonglivedassetstobedisposedof": 333000,
    "amortizationofprepaidmaintenance": 74000,
    "sharebasedcompensation": 93000,
    "amortizationoffinancingcosts": 116000,
    "deferredincometaxexpensebenefit": -1254000,
    "otheroperatingactivitiescashflowstatement": 5000,
    "increasedecreaseinaccountsreceivable": 182000,
    "increasedecreaseinduetorelatedparties": -6000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 267000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 854000,
    "netcashprovidedbyusedinoperatingactivities": -25980000,
    "paymentstoacquirebusinessesnetofcashacquired": 6189000,
    "paymentfordeposits": 325000,
    "paymentstoacquireequitymethodinvestments": 4000000,
    "paymentstoacquirepropertyplantandequipment": 1227000,
    "proceedsfromsecuritydepositandother": -7000,
    "netcashprovidedbyusedininvestingactivities": -11748000,
    "proceedsfromstockoptionsexercised": 1445000,
    "proceedsfromissuanceofcommonstock": 300000,
    "paymentsofstockissuancecosts": 58000,
    "proceedsfromissuanceofprivateplacement": 2462000,
    "paymentforfinancingcostsforatthemarketsales": 74000,
    "commonsharesreceivedandretiredforemployeetaxespaid": 14000,
    "repaymentsoflongtermlinesofcredit": 375000,
    "financeleaseprincipalpayments": 71000,
    "proceedsfrompaycheckprotectionprogramloan": 1141000,
    "netcashprovidedbyusedinfinancingactivities": 22799000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -14929000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 8843000,
    "interestpaidnet": 209000,
    "commonstockissuedforacquisition": 5000000,
    "initialfairvalueofcontingentconsiderationatacquisitiondate": 11130000,
    "holdbackliability": 600000,
    "capitalexpendituresincurredbutnotyetpaid": 2049000,
    "accountsreceivablefromagentforatthemarketsalesofcommonstocknetoffinancingcosts": 262000,
    "stockissued1": 169000,
    "equitymethodinvestmentownershippercentage": 0.05,
    "debtinstrumentmaturitydate": "2020-04-01",
    "equitymethodinvestmentdescription": "As of the date of this Report, Lineage's ownership interest in Oncocyte is less than 5%.",
    "commonstocksharesheldasavailableforsalesecurities": 353264,
    "propertyplantandequipmentusefullife": "P10Y",
    "lesseeoperatingleasetermofcontract": "P5Y",
    "finitelivedintangibleassetusefullife": "P5Y",
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "accountsreceivablesale": 103000,
    "restrictedcashincludedindepositsandothernoncurrentassets": 1700000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 3384000,
    "prepaidinsurance": 264000,
    "prepaidvendorsdepositsandserviceagreements": 646000,
    "otherassetscurrent": 295000,
    "restrictedcashandsecuritydepositforlease": 1850000,
    "prepaidexpensenoncurrent": 118000,
    "otherassetsnoncurrent": 88000,
    "employeerelatedliabilitiescurrent": 3556000,
    "cashholdbackliability": 600000,
    "otheraccountspayableandaccruedliabilities": 1596000,
    "severancecosts1": 1100000,
    "leaseholdimprovementsgross": 2100000,
    "netinvestmentinlease": 1100000,
    "operatingleaserightofuseasset": 3397000,
    "propertyplantandequipmentgross": 2480000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 1440000,
    "propertyplantandequipmentnet": 4437000,
    "constructioninprogressgross": 2087000,
    "cash": 6400000,
    "financeleaseweightedaveragediscountratepercent": 0.1127,
    "fairvalueofcontingentconsideration": 4000000,
    "finitelivedintangibleassetestimatedfairvalue": 440000,
    "contingentconsiderationliabilitycontractualvalue": 1500000,
    "businesscombinationcontingentconsiderationliability": 1210000,
    "acquirediprddetermaio": 14650000,
    "acquiredintangibleassetscustomerrelationship": 440000,
    "finitelivedintangibleassetsgross": 15090000,
    "finitelivedintangibleassetsaccumulatedamortization": -81000,
    "finitelivedintangibleassetsnet": 15009000,
    "equitymethodinvestmentaggregatecost": 10000000,
    "equitymethodinvestmentdescriptionofprincipalactivities": "If the issuance of shares of Oncocyte common stock having a market value of $5 million would exceed the number of shares issuable without shareholder approval under applicable stock exchange rules, Oncocyte may deliver a number of shares of common stock that would not exceed the number of shares permissible under stock exchange rules and an amount of cash necessary to bring the combined value of cash and shares to $5 million.",
    "clinicaltrialexpensereserveamount": 4000000,
    "estimatedclinicaltrialexpense": 12000000,
    "milestonepayment": 4000000,
    "researchanddevelopmentarrangementcontracttoperformforotherscostsincurredgross": 3000000,
    "paymentobligationamount": 433000,
    "leaseexpirationdate1": "2023-03-31",
    "preliminarycoveragemilestonepayment": 1000000,
    "businessacquisitioncostofacquiredentitytransactioncosts": 245000,
    "propertyplantandequipmentestimatedusefullives": "P10Y",
    "percentageofmarkupfeeallocatedbutnotcharged": 0.05,
    "professionalfees": 600000,
    "debtinstrumentfrequencyofperiodicpayment": "Payments of interest only on the principal balance were due monthly from the loan funding date, March 23, 2017, through October 31, 2017, and, beginning on November 1, 2017",
    "debtinstrumentperiodicpayment": 67000,
    "prepaymentfeeifprepaidtwoyearsormore": 0.01,
    "lineofcreditfacilityinterestrateatperiodend": 0.0325,
    "financingreceivableunamortizedloanfeecost": 68000,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 5.5,
    "commonstockpurchasewarrantssharesissued": 3383913,
    "classofwarrantorrightoutstanding": 3383913,
    "warrantsandrightsoutstandingmaturitydate": "2029-10-17",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 5200000,
    "commonstockcapitalsharesreservedforfutureissuance": 11000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 500000,
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "The price at which Restricted Stock may be issued or sold will be not less than 100% of fair market value.",
    "stockoptionexercisable": 100000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangelowerrangelimit": 2.78,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 5.9,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestednumberofshares": 265000,
    "allocatedsharebasedcompensationexpense": 466000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 8100000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P2Y6M",
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 3346000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablerestrictedstockoptionsgrantsinperiodgross": -272000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablegrantsinperiodgross": 3332000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsforfeitednumberofshares": 208000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 2155000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 208000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 1216000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 4.01,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 2.12,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 2.16,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageexerciseprice1": 3.58,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 201000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsvestedinperiodrsus": -20000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgrantsinperiodrsus": 136000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P7Y3M15D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0108,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.0373,
    "partialreleaseofvaluationallownces": 1250000,
    "deferredtaxassetsoperatinglosscarryforwards": 300000,
    "netoperatinglossexpirationperioddescription": "Between 2022 and 2040",
    "creditcarryforwardexpirationterm": "Between 2030 and 2040",
    "creditlosscarryforwardexpirationyear": 2022,
    "deferredtaxassetstaxcreditcarryforwardsresearch": 1800000,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 7600000,
    "unrecognizedtaxbenefits": 3052000,
    "otherinformationpertainingtoincometaxes": "The amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation.",
    "deferredtaxassetsequitymethodinvestments": 261000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1855000,
    "deferredtaxassetsequitymethodinvestment": 404000,
    "deferredtaxrightofuseliability": 1064000,
    "deferredtaxassetsothertaxcarryforwards": 168000,
    "deferredtaxrightofuseasset": -712000,
    "deferredtaxassetsintangiblesandfixedassets": -3129000,
    "deferredtaxassetsgross": 31752000,
    "deferredtaxassetsvaluationallowance": 31752000,
    "effectiveincometaxratereconciliationdeductions": 0.02,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.04,
    "effectiveincometaxratereconciliationtaxcreditsresearch": 0.01,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.24,
    "effectiveincometaxratecontinuingoperations": 0.04,
    "unrecognizedtaxbenefitsincreasesresultingfromcurrentperiodtaxpositions": 149000,
    "unrecognizedtaxbenefitsdecreasesresultingfrompriorperiodtaxpositions": 15000,
    "concentrationriskpercentage1": 0.45,
    "paymentsforproceedsfromtenantallowance": 1100000,
    "paymentsduetothelandlordforearlycancellation": 329000,
    "operatingleasepayments": 552000,
    "financeleaseinterestpaymentonliability": 9000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 536000,
    "operatingleaserightofuseliabilitiescurrent": 271000,
    "operatingleaserightofuseliabilitiesnoncurrent": 4091000,
    "operatingleaserightofleaseliabilities": 4362000,
    "financeleaserightofuseassetbeforeaccumulatedamortization": 523000,
    "financeleaserightofuseassetaccumulatedamortization": 180000,
    "financeleaserightofuseasset": 343000,
    "financeleaseliabilitycurrent": 151000,
    "financeleaseliabilitynoncurrent": 221000,
    "financeleaseliability": 372000,
    "operatingleaseweightedaverageremainingleaseterm1": "P6Y2M12D",
    "financeleaseweightedaverageremainingleaseterm1": "P2Y8M12D",
    "operatingleaseweightedaveragediscountratepercent": 0.1115,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 1030000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 1096000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 1000000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 889000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 869000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 1594000,
    "lesseeoperatingleaseliabilitypaymentsdue": 6478000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 1887000,
    "leasseetenantimprovementallowancenetofadministrativefee": -229000,
    "presentvalueofnetminimumleasepayments": 4362000,
    "financeleaseliabilitypaymentsduenexttwelvemonths": 185000,
    "financeleaseliabilitypaymentsdueyeartwo": 124000,
    "financeleaseliabilitypaymentsdueyearthree": 124000,
    "financeleaseliabilitypaymentsdue": 433000,
    "financeleaseliabilityundiscountedexcessamount": 61000,
    "paymentsfortenantimprovements": 1100000,
    "tenantimprovements": 1300000,
    "tenantimprovementallowanceremainingbalance": 200000
  },
  {
    "date": "2019-12-30",
    "symbol": "OCX",
    "period": "FY",
    "entityregistrantname": "OncoCyte Corp",
    "entitycentralindexkey": 1642380,
    "documenttype": "10-K",
    "documentperiodenddate": "2019-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "true",
    "entityshellcompany": "false",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "cashandcashequivalentsatcarryingvalue": 22072000,
    "equitysecuritiesfvni": 379000,
    "prepaidexpenseandotherassetscurrent": 505000,
    "assetscurrent": 4000000,
    "rightofuseassetsmachineryandequipmentnet": 3728000,
    "depositsandothernoncurrentassets": 2211000,
    "equitymethodinvestments": 10000000,
    "assets": 4000000,
    "duetorelatedpartiescurrent": 6000,
    "accountspayablecurrent": 469000,
    "accountspayableandotheraccruedliabilitiescurrent": 2610000,
    "loanspayablecurrent": 1125000,
    "rightofuseandfinancingleaseliabilitiescurrent": 230000,
    "liabilitiescurrent": 4440000,
    "longtermloanspayable": 1905000,
    "rightofuseandfinancingleaseliabilitiesnoncurrent": 2676000,
    "liabilities": 9021000,
    "commonstockvalue": 5000000,
    "retainedearningsaccumulateddeficit": -93745000,
    "stockholdersequity": 4000000,
    "liabilitiesandstockholdersequity": 4000000,
    "preferredstocksharesauthorized": 5000000,
    "commonstocksharesauthorized": 85000000,
    "commonstocksharesissued": 57032000,
    "commonstocksharesoutstanding": 57032000,
    "researchanddevelopmentexpense": 696000,
    "generalandadministrativeexpense": 438000,
    "sellingandmarketingexpense": 108000,
    "operatingexpenses": 22239000,
    "operatingincomeloss": -22239000,
    "gainslossesonextinguishmentofdebt": 153000,
    "interestincomeexpensenet": 299000,
    "marketablesecuritiesunrealizedgainloss": -49000,
    "incomelossfromequitymethodinvestments": -281000,
    "othernonoperatingincomeexpense": -3000,
    "nonoperatingincomeexpense": -187000,
    "netincomeloss": -22426000,
    "earningspersharebasicanddiluted": -0.44,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 51296000,
    "comprehensiveincomenetoftax": -22426000,
    "sharesoutstanding": 57032000,
    "stockissuedduringperiodvaluesharebasedcompensationgross": 2995000,
    "stockissuedduringperiodvaluenewissues": 3000000,
    "stockissuedduringperiodsharesnewissues": 15793000,
    "stockissuedduringperiodvalueother": -3317000,
    "stockissuedduringperiodvaluestockoptionsexercised": 943000,
    "stockissuedduringperiodsharesstockoptionsexercised": 575000,
    "stockandwarrantsissuedduringperiodvaluepreferredstockandwarrants": 370000,
    "depreciation": 344000,
    "amortizationofrightofuseassetsandliabilities": 7000,
    "amortizationofprepaidmaintenance": 37000,
    "sharebasedcompensation": 111000,
    "amortizationoffinancingcosts": 116000,
    "issuanceofstockandwarrantsforservicesorclaims": 234000,
    "otheroperatingactivitiescashflowstatement": 107000,
    "increasedecreaseinduetorelatedparties": -2094000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 202000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 741000,
    "netcashprovidedbyusedinoperatingactivities": -19715000,
    "paymentstoacquireequitymethodinvestments": 11245000,
    "paymentstoacquirepropertyplantandequipment": 918000,
    "paymentstosecuritydepositandother": 252000,
    "netcashprovidedbyusedininvestingactivities": -12415000,
    "proceedsfromstockoptionsexercised": 943000,
    "proceedsfromissuanceofcommonstock": 48850000,
    "paymentsofstockissuancecosts": 3288000,
    "proceedsfromrepaymentsofdebt": 3000000,
    "repaymentsofprincipalandbankfeesfromrefinancingofbankloan": 516000,
    "repaymentsofdebt": 667000,
    "financeleaseprincipalpayments": 454000,
    "netcashprovidedbyusedinfinancingactivities": 47868000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 15738000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 23772000,
    "interestpaidnet": 171000,
    "deferredfinalcommitmentfeeforbankloan": 200000,
    "equitymethodinvestmentownershippercentage": 0.2,
    "equitymethodinvestmentdescription": "As of the date of this Report, Lineage's ownership interest in Oncocyte is below 10%.",
    "commonstocksharesheldasavailableforsalesecurities": 35326,
    "propertyplantandequipmentusefullife": "P10Y",
    "lesseeoperatingleasetermofcontract": "P5Y",
    "intangibleassetsnoncashcharge": 625000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "numberofoperatingsegments": 1,
    "leasetermdescription": "Oncocyte continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially of the fair value of the underlying asset. ",
    "restrictedcashincludedindepositsandothernoncurrentassets": 1700000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 3384000,
    "writeoffindepreciatedassets": 900000,
    "prepaidinsurance": 80000,
    "prepaidvendorsdepositsandserviceagreements": 389000,
    "otherassetscurrent": 36000,
    "restrictedcashandsecuritydepositforlease": 1850000,
    "prepaidexpensenoncurrent": 268000,
    "otherassetsnoncurrent": 93000,
    "employeerelatedliabilitiescurrent": 1287000,
    "otheraccountspayableandaccruedliabilities": 1323000,
    "propertyplantandequipmentgross": 1215000,
    "operatingleaserightofuseasset": 2856000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 343000,
    "propertyplantandequipmentnet": 3728000,
    "percentageofmarkupfeeallocatedbutnotcharged": 0.05,
    "termofpayment": "P30D",
    "interestonunpaidoverdueinvoice": 0.15,
    "operatingleasepayments": 141000,
    "professionalfees": 400000,
    "usefees": 1242000,
    "equitymethodinvestmentaggregatecost": 10000000,
    "clinicaltrialexpensereserveamount": 4000000,
    "estimatedclinicaltrialexpense": 12000000,
    "milestonepayment": 1000000,
    "milestonepaymentdescription": "In the event Razor receives the final positive coverage decision from CMS/MolDx for reimbursement of patient costs of DetermaRx™ within 12 months after the Initial Closing, Oncocyte will pay Encore $4 million (\"CMS Final Milestone Payment\").",
    "researchanddevelopmentarrangementcontracttoperformforotherscostsincurredgross": 3000000,
    "paymentobligationamount": 450000,
    "leaseexpirationdate1": "2023-03-31",
    "preliminarycoveragemilestonepayment": 1000000,
    "businessacquisitioncostofacquiredentitytransactioncosts": 245000,
    "propertyplantandequipmentestimatedusefullives": "P10Y",
    "debtinstrumentfrequencyofperiodicpayment": "Payments of interest only on the principal balance were due monthly from the draw date through October 31, 2017, and, beginning on November 1, 2017",
    "debtinstrumentperiodicpayment": 67000,
    "debtinstrumentmaturitydate": "2020-04-01",
    "prepaymentfeeifprepaidtwoyearsormore": 0.01,
    "longtermdebtpercentagebearingfixedinterestrate": 0.05,
    "debtdefaultlegalactionamount": 50000,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 5.5,
    "deferredfinancecostsnet": 62000,
    "paymentsofdebtissuancecosts": 196000,
    "debtinstrumentinterestrateduringperiod": 0.0475,
    "longtermdebtmaturitiesrepaymentsofprincipalinnexttwelvemonths": 1258000,
    "longtermdebtmaturitiesrepaymentsofprincipalinyeartwo": 1561000,
    "longtermdebtmaturitiesrepaymentsofprincipalinyearthree": 578000,
    "paymentsofprincipalandinterest": 3397000,
    "loanpayableamountsrepresentinginterest": -197000,
    "debtinstrumentcarryingamount": 3200000,
    "loanspayable": 3030000,
    "commonstockpurchasewarrantssharesissued": 3383913,
    "classofwarrantorrightoutstanding": 3383913,
    "warrantsandrightsoutstandingmaturitydate": "2027-03-23",
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 5200000,
    "commonstockcapitalsharesreservedforfutureissuance": 11000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 500000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y11D",
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "The exercise price of stock options granted under the 2018 Incentive Plan must be equal to the fair market of Oncocyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of Oncocyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years.",
    "fairmarketvalueofcommonstockpercentage": 1.1,
    "stockoptionexercisable": 100000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangelowerrangelimit": 3.06,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 5.95,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestednumberofshares": 47500,
    "allocatedsharebasedcompensationexpense": 101000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 2831000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 6500000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P2Y7M6D",
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.87,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 6742000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedoptionpoolincrease": 6000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablegrantsinperiodgross": 4089000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablerestrictedstockoptionsgrantsinperiodgross": -170000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsforfeitednumberofshares": 362000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardrestrictedstockoptionsgrantsinperiodgross": 85000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 362000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 2206000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 3.98,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 1.64,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 3.42,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageexerciseprice1": 3.2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P6Y11D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0205,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.7902,
    "deferredtaxassetsoperatinglosscarryforwards": 700000,
    "netoperatinglossexpirationperioddescription": "between 2020 and 2023",
    "deferredtaxassetstaxcreditcarryforwardsresearch": 1500000,
    "creditcarryforwardexpirationterm": "between 2030 and 2039",
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 4300000,
    "unrecognizedtaxbenefits": 2888000,
    "deferredtaxassetsequitymethodinvestments": 394000,
    "deferredtaxassetspatentsandfixedassets": 949000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1166000,
    "deferredtaxassetsequitymethodinvestment": 81000,
    "deferredtaxrightofuseliability": 764000,
    "deferredtaxrightofuseasset": -749000,
    "deferredtaxassetsgross": 24186000,
    "deferredtaxassetsvaluationallowance": 24186000,
    "effectiveincometaxratereconciliationdeductions": -0.02,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.02,
    "effectiveincometaxratereconciliationtaxcreditsresearch": -0.02,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.19,
    "unrecognizedtaxbenefitsincreasesresultingfromcurrentperiodtaxpositions": 1301000,
    "unrecognizedtaxbenefitsdecreasesresultingfrompriorperiodtaxpositions": 1587000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 2866000,
    "propertysubjecttooravailableforfinanceleasegross": 209000,
    "accumulateddepreciationforfinancelease": -93000,
    "propertyplantandequipmentnetfinancelease": 116000,
    "financeleaseliabilitycurrent": 71000,
    "financeleaseliabilitynoncurrent": 58000,
    "financeleaseliability": 129000,
    "operatingleaseweightedaverageremainingleaseterm1": "P7Y3M19D",
    "financeleaseweightedaverageremainingleaseterm1": "P1Y9M18D",
    "operatingleaseweightedaveragediscountratepercent": 0.112,
    "financeleaseweightedaveragediscountratepercent": 0.096,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 394000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 879000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 951000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 850000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 839000,
    "lesseeoperatingleaseliabilitypaymentsdueafteryearfive": 2463000,
    "lesseeoperatingleaseliabilitypaymentsdue": 6376000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 2279000,
    "leasseetenantimprovementallowancenetofadministrativefee": -1320000,
    "operatingleaseliability": 2777000,
    "financeleaseliabilitypaymentsduenexttwelvemonths": 81000,
    "financeleaseliabilitypaymentsdueyeartwo": 60000,
    "financeleaseliabilitypaymentsdue": 141000,
    "financeleaseliabilityundiscountedexcessamount": 12000
  },
  {
    "date": "2018-12-30",
    "symbol": "OCX",
    "period": "FY",
    "entityregistrantname": "OncoCyte Corp",
    "entitycentralindexkey": 1642380,
    "documenttype": "10-K",
    "documentperiodenddate": "2018-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "true",
    "entityshellcompany": "false",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2018,
    "cashandcashequivalentsatcarryingvalue": 8034000,
    "equitysecuritiesfvni": 428000,
    "prepaidexpenseandotherassetscurrent": 180000,
    "assetscurrent": 8642000,
    "propertyplantandequipmentnet": 614000,
    "depositsandothernoncurrentassets": 262000,
    "assets": 9518000,
    "duetorelatedpartiescurrent": 2101000,
    "accountspayablecurrent": 166000,
    "accountspayableandotheraccruedliabilitiescurrent": 2109000,
    "loanspayablecurrent": 800000,
    "capitalleaseobligationscurrent": 209000,
    "liabilitiescurrent": 5561000,
    "longtermloanspayable": 347000,
    "capitalleaseobligationsnoncurrent": 187000,
    "liabilities": 6095000,
    "commonstockvalue": 74742000,
    "retainedearningsaccumulateddeficit": -71319000,
    "stockholdersequity": -71319000,
    "liabilitiesandstockholdersequity": 9518000,
    "preferredstocksharesauthorized": 5000000,
    "commonstocksharesauthorized": 85000000,
    "commonstocksharesissued": 40664000,
    "commonstocksharesoutstanding": 40664000,
    "researchanddevelopmentexpense": 882000,
    "generalandadministrativeexpense": 375000,
    "sellingandmarketingexpense": 310000,
    "operatingexpenses": 15202000,
    "operatingincomeloss": -15202000,
    "interestincomeexpensenet": -216000,
    "marketablesecuritiesunrealizedgainloss": -427000,
    "othernonoperatingincomeexpense": 91000,
    "nonoperatingincomeexpense": -552000,
    "netincomeloss": -15754000,
    "earningspersharebasicanddiluted": -0.42,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 37850000,
    "comprehensiveincomenetoftax": -15754000,
    "sharesoutstanding": 40664000,
    "stockissuedduringperiodvaluesharebasedcompensationgross": 1479000,
    "stockissuedduringperiodvaluestockoptionsexercised": 58000,
    "stockissuedduringperiodsharesstockoptionsexercised": 20000,
    "newaccountingpronouncementorchangeinaccountingprincipleeffectofadoptionquantification": -888000,
    "stockissuedduringperiodvaluenewissues": 13592000,
    "stockissuedduringperiodsharesnewissues": 9192000,
    "stockissuedduringperiodvalueother": -355000,
    "depreciation": 438000,
    "amortizationofintangibleassets": 121000,
    "amortizationofprepaidmaintenance": 18000,
    "impairmentofintangibleassetsexcludinggoodwill": 625000,
    "sharebasedcompensation": 275000,
    "dividendincomeoperating": 96000,
    "amortizationoffinancingcosts": 116000,
    "otheroperatingactivitiescashflowstatement": 23000,
    "increasedecreaseinduetorelatedparties": 2000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 11000,
    "increasedecreaseinaccountspayableandaccruedliabilities": 1002000,
    "netcashprovidedbyusedinoperatingactivities": -11649000,
    "paymentstoacquirepropertyplantandequipment": 31000,
    "netcashprovidedbyusedininvestingactivities": -31000,
    "proceedsfromstockoptionsexercised": 58000,
    "proceedsfromissuanceofcommonstock": 10000000,
    "paymentsofstockissuancecosts": 65000,
    "proceedsfromsaleofcommonsharesandwarrants": 3592000,
    "financingcoststoissuecommonsharesandwarrants": -290000,
    "repaymentsofdebt": 800000,
    "repaymentsoflongtermcapitalleaseobligations": 381000,
    "netcashprovidedbyusedinfinancingactivities": 12114000,
    "cashandcashequivalentsperiodincreasedecrease": 434000,
    "interestpaidnet": 142000,
    "fairvalueofassetsacquired": 209000,
    "availableforsalesecuritiesequitysecuritiescurrent": 428000,
    "proceedsfromissuanceinitialpublicoffering": 37400000,
    "saleofstocknumberofsharesissuedintransaction": 10733334,
    "dividendscommonstockcash": 96000,
    "commonstocksharesheldasavailableforsalesecurities": 35326,
    "finitelivedintangibleassetusefullife": "P5Y",
    "intangibleassetsnoncashcharge": 625000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "numberofoperatingsegments": 1,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 4035000,
    "machineryandequipmentwriteoffamount": 150000,
    "employeerelatedliabilitiescurrent": 1303000,
    "otheraccountspayableandaccruedliabilities": 806000,
    "finitelivedintangibleassetsgross": 625000,
    "finitelivedintangibleassetsaccumulatedamortization": 625000,
    "researchanddevelopmentexpenseincludingamortizationofintangibleasset": 121000,
    "propertyplantandequipmentgross": 1562000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 948000,
    "percentageofmarkupfeeallocatedbutnotcharged": 0.05,
    "termofpayment": "P30D",
    "interestonunpaidoverdueinvoice": 0.15,
    "allocatedservicesandfacilityusefeepayable": 2100000,
    "minimumfixedpaymentduesharedfacilityagreement": 131000,
    "losscontingencydamagesawardedvalue": 300000,
    "usefees": 1567000,
    "debtinstrumentbasisspreadonvariablerate1": 0.0075,
    "debtinstrumentinterestrateduringperiod": 0.0625,
    "debtinstrumentmaturitydate": "2020-04-01",
    "classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": 500000,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 3.25,
    "deferredfinancecostsnet": 62000,
    "paymentsofdebtissuancecosts": 196000,
    "unamortizeddeferredfinancingcosts": 36000,
    "longtermdebtmaturitiesrepaymentsofprincipalinnexttwelvemonths": 843000,
    "longtermdebtmaturitiesrepaymentsofprincipalinyeartwo": 386000,
    "paymentsofprincipalandinterest": 1229000,
    "loanpayableamountsrepresentinginterest": -46000,
    "debtinstrumentcarryingamount": 1183000,
    "loanspayable": 1147000,
    "classofwarrantorrightexercisedperiod": "P5Y",
    "classofwarrantorrightunissued": 4035339,
    "classofwarrantorrightoutstanding": 4035339,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesauthorized": 5200000,
    "commonstockcapitalsharesreservedforfutureissuance": 5000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 500000,
    "sharebasedcompensationarrangementbysharebasedpaymentawarddescription": "The exercise price of stock options granted under the 2018 Incentive Plan must be equal to the fair market of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years.",
    "fairmarketvalueofcommonstockpercentage": 1.1,
    "stockoptionsexercisable": 100000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P6Y9M18D",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangelowerrangelimit": 1.34,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeupperrangelimit": 7.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 4532000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedstockoptions": 2700000,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognizedperiodforrecognition1": "P3Y3M19D",
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 2.21,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestednumberofshares": 4639000,
    "sharesavailableforgrantoutstandingapprovaloftwothousandeighteenincentiveplan": 5000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsavailablegrantsinperiodgross": 411000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsnonvestedoptionsforfeitednumberofshares": 50000,
    "sharesavailableforgrantoptionstermination": -76000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 50000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 2348000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 2.87,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 2.84,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 1.95,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageexerciseprice1": 2.82,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P5Y7M24D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0285,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.7551,
    "deferredtaxassetsnet": 6800000,
    "incometaxexaminationdescription": "The federal portion of the deferred tax assets and liabilities were re-rated from 34% to 21% percent pursuant to the 2017 Tax Act.",
    "deferredtaxassetsoperatinglosscarryforwards": 1300000,
    "netoperatinglossexpirationperioddescription": "between 2020 and 2023",
    "deferredtaxassetstaxcreditcarryforwardsresearch": 1200000,
    "creditcarryforwardexpirationterm": "between 2030 and 2038",
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 4800000,
    "otherinformationpertainingtoincometaxes": "The amount of taxable income that can be offset by NOL carryforwards after a change in control (generally greater than 50% change in ownership within a three-year period) of a loss corporation.",
    "deferredtaxassetsequitymethodinvestments": 393000,
    "deferredtaxassetspatentsandfixedassets": 523000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1326000,
    "deferredtaxassetsgross": 19890000,
    "deferredtaxassetsvaluationallowance": 19890000,
    "effectiveincometaxratereconciliationstateandlocalincometaxes": 0.1,
    "effectiveincometaxratereconciliationtaxcreditsresearch": 0.01,
    "effectiveincometaxratereconciliationotherreconcilingitemspercent": -0.01,
    "effectiveincometaxratereconciliationchangeindeferredtaxassetsvaluationallowance": -0.31,
    "capitalleasepaymentterm": "P36M",
    "capitalleasesfutureminimumpaymentsinterestincludedinpayments": 48000,
    "capitalleasesfutureminimumpaymentsduecurrent": 420000,
    "capitalleasesfutureminimumpaymentsdueintwoyears": 140000,
    "capitalleasesfutureminimumpaymentsdueinthreeyears": 60000,
    "capitalleasesfutureminimumpaymentsdue": 620000,
    "capitalleasesfutureminimumpaymentspresentvalueofnetminimumpayments": 572000
  }
]